Zafinofusp alfa - Denali Therapeutics
Alternative Names: DNL-126; ETV:N-sulphoglucosamine sulphohydrolase; ETV:SGSH; Recombinant sulphoglucosamine sulphohydrolase - Denali TherapeuticsLatest Information Update: 20 Aug 2026
At a glance
- Originator Denali Therapeutics Inc
- Class Hydrolases; Recombinant fusion proteins
- Mechanism of Action N-sulfoglucosamine sulfohydrolase replacements
-
Orphan Drug Status
Yes - Mucopolysaccharidosis III
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Mucopolysaccharidosis III
Highest Development Phases
- Phase I/II Mucopolysaccharidosis III
Most Recent Events
- 06 Feb 2026 Denali expects a BLA submission for Zafinofusp alfa for MPS IIIA in 2027
- 06 Feb 2026 Denali expects approval for Zafinofusp alfa for MPS IIIA in 2027
- 05 Feb 2026 Efficacy, pharmacodynamics and adverse events data from phase I/II trial in Mucopolysaccharidosis III A released by Denali Therapeutics